Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage | Zendy

Alona Finkel | Zendy; Lior Liba | Zendy; Einav Simon | Zendy; Tova Bick | Zendy; Elad Prinz | Zendy; Edmond Sabo | Zendy; Ofer BenIzhak | Zendy; Dov Hershkovitz | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Subclonality for BRAF Mutation in Papillary Thyroid Carcinoma Is Associated With Earlier Disease Stage

Author(s) -

Alona Finkel,

Lior Liba,

Einav Simon,

Tova Bick,

Elad Prinz,

Edmond Sabo,

Ofer BenIzhak,

Dov Hershkovitz

Publication year - 2016

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-4031

Subject(s) - mutation , thyroid carcinoma , pathology , pathological , biology , stage (stratigraphy) , cancer research , point mutation , carcinoma , v600e , medicine , thyroid , gene , genetics , paleontology

The presence of driver mutations only in a subset of tumor cells within a single lesion, defined as subclonality, is being appreciated as a clinically significant factor. BRAF mutation is the most common driver mutation in papillary thyroid carcinoma (PTC). There are conflicting data in the literature regarding the presence of BRAF mutation subclonality in PTC and its clinical significance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research